Wheeler Bio to Expand Their Portable CMC® Platform Capabilities with Licenses from ATUM's miFuc™ Technology
Wheeler Bio, Inc., a fast-growing contract development and manufacturing organization (CDMO), announced today the expansion of its capabilities by licensing ATUM’s cutting-edge miFuc™ platform, which enables the expression of recombinant proteins with afucosylated glycans. This licensing agreement gives Wheeler Bio’s clients the ability to produce therapeutic antibodies with enhanced effector engagement and antibody-dependent cellular cytotoxicity, enabling broader therapeutic windows and reduced toxicity.
Wheeler Bio to Expand Their Portable CMC® Platform Capabilities with Licenses from ATUM's miFuc™ Technology